WASHINGTON — The odds of Rand Paul facing a penalty for his severely delayed disclosure of a stock purchase are slim, based on recent history of similar cases in the U.S. Senate.
The Senate Select Committee on Ethics, which oversees such lapses, hasn’t issued a disciplinary sanction in more than a decade, even after a flurry of questionable stock trades by members came to light last year amid the coronavirus pandemic.
On Wednesday, The Washington Post revealed that in late February 2020 Paul's wife bought stock valued between $1,000 and $15,000 in Gilead Sciences, which produces remdesivir — an antiviral used to treat COVID-19.
